Phio’s INTASYL therapy PH-762 shows 100% tumor clearance in skin cancer dose-escalation study

Phio Pharmaceuticals Corporation reported that its lead INTASYL-based RNA interference candidate, PH-762, produced notably strong pathology responses in the final and highest-dose cohort of its Phase 1b intratumoral skin cancer study, with one patient showing complete, 100 percent tumour clearance and another demonstrating more than 90 percent clearance approximately five weeks after treatment. The company indicated that the Safety Monitoring Committee allowed escalation through to the maximal planned dose without dose-limiting toxicities, which strengthens the safety narrative around its self-delivering RNAi platform. For a small-cap clinical-stage company trying to prove that locally delivered RNAi can reprogram the tumour microenvironment in cutaneous malignancies such as cutaneous squamous cell carcinoma, this is the kind of high-signal data point that helps bridge the gap from preclinical promise to human proof-of-mechanism.

How PH-762’s intratumoral RNAi approach targets PD-1 to unlock local antitumor immunity

PH-762 is built on Phio’s INTASYL technology, a self-delivering RNA interference construct designed to silence expression of programmed cell death protein 1 (PD-1) at or near the tumour site. Instead of relying on systemic monoclonal antibodies to block the PD-1/PD-L1 axis, Phio is attempting to reduce PD-1 expression locally via RNAi in tumour-infiltrating lymphocytes and other immune cells that populate the lesion. Company materials have previously suggested that intratumoral delivery permits higher local activity with potentially lower systemic exposure, which could be important for frailer patients or for skin cancers in anatomically sensitive areas. By downregulating PD-1 at the lesion, PH-762 is meant to make tumour-resident immune cells less “exhausted,” thereby improving recognition and killing of tumour cells. This is conceptually aligned with the broader industry shift toward in situ immunomodulation, where the tumour itself is turned into an immunization hub rather than relying solely on systemic immune activation.

From a mechanistic standpoint, this is a differentiated angle compared with the better-known systemic RNAi drugs developed by companies such as Alnylam Pharmaceuticals, which target hepatic genes via GalNAc conjugation. Phio’s approach is more interventional and more oncology-specific, utilising direct lesion injection to achieve concentration at the disease site. That makes it more comparable to intratumoral immunotherapy strategies such as those explored by Replimune Group in oncolytic immunotherapy, or even to some of the mRNA and viral vector efforts aimed at turning cold tumours hot. The distinction is that PH-762 is not trying to infect or transfect broadly; it is trying to silence a well-validated checkpoint and let the immune system do the rest. For search and discovery purposes, this creates a useful SEO cluster around “intratumoral RNAi,” “local PD-1 silencing,” “INTASYL delivery,” and “non-surgical skin cancer immunotherapy,” all of which carry long-tail relevance.

Why the final maximum dose cohort data strengthen translational confidence for cutaneous squamous cell carcinoma treatment paths

The importance of the final cohort data is that it gives a glimpse of the dose–response relationship in human lesions. Phio reported that among the three patients in the top-dose cohort, one lesion showed complete histopathological clearance, a second showed tumour reduction greater than 90 percent, and the third still surpassed a 50 percent reduction threshold. When these results are placed alongside the broader dataset from five cohorts and 18 treated patients, including 16 with cutaneous squamous cell carcinoma, the company can now point to multiple complete responses and several high-grade partial responses, all assessed on pathology at a uniform time point of about five weeks post-treatment. That kind of consistency in timing matters because it reduces noise in interpreting whether the agent is producing true immune-mediated clearance versus post-biopsy changes or wound-healing artefacts.

In translational terms, this matters for two reasons. First, cSCC often presents as a lesion that is technically amenable to surgery, but patients may be elderly, may have multiple lesions, or may prefer a non-surgical option for cosmetic or functional reasons. A percutaneously administered, intratumoral agent that can clear or debulk visible disease in a matter of weeks immediately becomes interesting to dermatologic oncologists. Second, showing that the maximal dose can be delivered without dose-limiting toxicity gives Phio room to define a recommended Phase 2 dose that is actually biologically active, not just safe. Early oncology trials frequently stall at “safe but soft” doses; here, the company can argue that it has observed meaningful activity at the top dose, and that further expansion cohorts can be powered around that signal. The company also highlighted the absence of clinically meaningful systemic adverse events at the final escalation level, which, if confirmed in larger sets, will support the core selling point of INTASYL as a controllable, locally acting RNAi modality.

How PH-762 compares with emerging intratumoral and RNAi-based immuno-oncology strategies from other biopharma players

In the current immuno-oncology landscape, most of the commercial value still sits with systemic checkpoint inhibitors from large companies, but there is an active second tier of innovation focused on locally delivered agents that can reshape a hostile tumour microenvironment. Replimune has been pursuing oncolytic immunotherapies that combine local tumour destruction with immune priming. Moderna and several other mRNA players have showcased intratumoral mRNA constructs to express costimulatory molecules or cytokines directly in the lesion. Smaller players in the RNAi and oligonucleotide space have been exploring self-delivering or vectorised RNAi concepts to target immune evasion genes. Against that backdrop, Phio’s INTASYL/PH-762 program sits in a niche that is still relatively uncrowded: self-delivering, intratumoral RNAi aimed at a checkpoint target that has already been clinically validated in antibody form.

That niche positioning gives Phio some SEO and editorial leverage. Readers searching for “intratumoral immunotherapy vs systemic immunotherapy,” “RNAi for skin cancer,” or even “local PD-1 blockade alternatives” can be directed to this program as an example of how gene-silencing tools are moving from hepatology to oncology. It also allows comparative framing: unlike oncolytic viruses, RNAi constructs do not need to replicate; unlike intratumoral cytokines, they do not necessarily produce the same level of inflammatory adverse events; and unlike systemic antibodies, they do not require repeated full-body exposure. The trade-off, of course, is that activity will be lesion-specific, so showing that cleared lesions stay cleared over time will be essential. If Phio can later show abscopal or distant-site effects, that would broaden the story considerably, but that has not yet been established in these early cohorts. Editorially, it is accurate to say that PH-762 demonstrates that RNAi can be a tool in tumour microenvironment engineering, in the same conversation as oncolytic, mRNA, and STING-targeting approaches.

What the current results may signal for Phio Pharmaceuticals’ clinical development plans and investor sentiment in 2026

For capital markets audiences tracking NASDAQ: PHIO, these pathology results are likely to be read as a positive but still early-stage inflection. Micro-cap immuno-oncology names tend to trade on discrete data events, and a report of complete tumour clearance in a top-dose cohort fits that pattern. However, investors will want to see several items before assigning higher probability to commercialisation: durability of clearance beyond the initial five-week window, expansion into a larger or multi-centre cohort, clarity on which skin cancer subtypes will be prioritised, and evidence that manufacturing and delivery of INTASYL constructs can scale. If the company can deliver follow-up data showing that cleared lesions remain disease-free, the risk–reward balance improves. If, on the other hand, responses prove transient, the program could be repositioned more as a neoadjuvant or debulking adjunct rather than a definitive therapy. That is still a legitimate market, particularly in older cSCC patients, but it changes the revenue model.

Sentiment therefore can be described as cautiously constructive. The safety profile at maximum dose is a clear positive. The demonstration of multiple complete or near-complete responses across the trial is another positive. The small sample size, single-arm design, and short follow-up are the counterweights. For 2026 planning, the company now has a narrative it can take to investigators, to potential partners, and to patient communities: intratumoral RNAi against PD-1 can work, it can be delivered safely, and it may serve patients who do not want or cannot undergo surgery. That is a commercially intelligible and medically relevant story. It also serves the broader industry conversation about diversifying checkpoint inhibition beyond antibodies and into nucleic-acid-based tools. For SEO purposes, this provides a strong closing cluster around “Phase 1b intratumoral RNAi data,” “PD-1 silencing in skin cancer,” “non-surgical cSCC treatment options,” and “clinical-stage immuno-oncology micro-cap updates.”